» Articles » PMID: 25450584

The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets

Overview
Journal Arch Med Res
Specialty General Medicine
Date 2014 Dec 3
PMID 25450584
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is a public health issue in developing countries. Although the Pap smear and colposcopy remain the major strategies for detection, most cases are diagnosed in the late stages. Therefore, a major concern has been to develop early diagnostic approaches and more effective treatments. Molecular pathways that participate in cervical malignant transformation have emerged as promising directed therapeutic targets. In this review, we explore some of the major pathways implicated in cervical cancer development, including RAF/MEK/ERK, phosphatidylinositol-3 kinase (PI3K/AKT), Wnt/b-catenin, apoptosis and coupled membrane receptor signaling. We focus on the role of these pathways in cervical carcinogenesis, their alterations and the consequences of these abnormalities. In addition, the most recent preclinical and clinical data on the rationally designed target-based agents that are currently being tested against elements of these pathways are reviewed.

Citing Articles

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.

Hyeon D, Nam D, Shin H, Jeong J, Jung E, Cho S Mol Cancer. 2025; 24(1):77.

PMID: 40087745 DOI: 10.1186/s12943-025-02256-3.


Targeting the TGF-β-p21 axis: a critical regulator of bleomycin-induced cell cycle arrest and apoptosis in vitro-implication for progressive cervical cancer therapy.

Shrivastava S, Ratnacaram C Med Oncol. 2025; 42(4):85.

PMID: 40019671 DOI: 10.1007/s12032-025-02624-5.


Loss of E-cadherin Activates EGFR-MEK/ERK Signaling, Promoting Cervical Cancer Progression.

Yun H, Han G, Wee D, Chay D, Chung J, Kim J Cancer Genomics Proteomics. 2025; 22(2):271-284.

PMID: 39993806 PMC: 11880930. DOI: 10.21873/cgp.20501.


Adenosinergic Signalling in Cervical Cancer Microenvironment.

Iser I, Bertoni A, Beckenkamp L, Consolaro M, Maria-Engler S, Wink M Expert Rev Mol Med. 2025; 27():e5.

PMID: 39762204 PMC: 11707834. DOI: 10.1017/erm.2024.30.


Drugs and drug targets for the treatment of HPV-positive cervical cancer.

Burmeister C, Khan S, Prince S Tumour Virus Res. 2024; 19():200309.

PMID: 39709045 PMC: 11733058. DOI: 10.1016/j.tvr.2024.200309.